RayzeBio

RayzeBio is committed to improving the prognosis of cancer patients by harnessing the power of targeted radionuclides. As an emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative and robust pipeline targeting validated oncology drug targets to deliver alpha particle-emitting radionuclides such as Actinium-225.